 MediWound Ltd. MDWD, a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a Biologics License Application BLA to the U.S. Food and Drug Administration FDA seeking the approval of NexoBrid for eschar removal debridement in adults with deep partial-thickness andor full-thickness thermal burns. The BLA submission includes a comprehensive set of manufacturing data, multiple preclinical and clinical studies including the pivotal U.S. Phase 3 DETECT study of NexoBrid in adult patients with deep partial and full-thickness thermal burns up to 30 of total body surface area. 